Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience
Version of Record online: 8 FEB 2007
European Journal of Haematology
Volume 78, Issue 4, pages 290–296, April 2007
How to Cite
Rodríguez, J., Conde, E., Gutiérrez, A., Arranz, R., Gandarillas, M., Leon, A., Ojanguren, J., Sureda, A., Carrera, D., Bendandi, M., Moraleda, J., Ribera, J. M., Albo, C., Morales, A., García, J. C., Fernández, P., Cañigral, G., Bergua, J., Caballero, M. D. and On behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO – Spanish lymphoma/autologous bone marrow transplant study group) (2007), Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. European Journal of Haematology, 78: 290–296. doi: 10.1111/j.1600-0609.2007.00815.x
- Issue online: 8 FEB 2007
- Version of Record online: 8 FEB 2007
- Accepted for publication 12 December 2006
- angioimmunoblastic T-cell lymphoma;
- autologous transplantation
Objectives: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004.
Methods: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%).
Results: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
Conclusions: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT. Patients who are transplanted in a refractory disease state do not benefit from this procedure.